Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
601 questions in 75 reviews · Schizophrenia
current versionsNo studies 601 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE Repeated need for tranquillisation within 24 hours ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE Global outcome ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: c. QUETIAPINE Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL Repeated need for tranquillisation within 24 hours ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE Repeated need for tranquillisation within 24 hours ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: a. RISPERIDONE + OXCARBAZEPINE Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID Repeated need for tranquillisation within 24 hours ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID Global outcome ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs COMBINATION: b. RISPERIDONE + VALPROIC ACID Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: a. HALOPERIDOL Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OTHER ANTIPSYCHOTIC: b. OLANZAPINE Repeated need for tranquillisation within 24 hours ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation) Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation) (2018) · Cochrane | no estimate extracted | NR | No studies |
Noradrenaline reuptake inhibitors vs placebo Cognitive functioning: significant response or improvement in cognitive functioning · adults with schizophrenia Selective noradrenaline reuptake inhibitors for schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data Subjective well‐being · people with serious mental illness and co‐occurring substance misuse Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance… (2018) · Cochrane | no estimate extracted | NR | No studies |
RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) · people with serious mental illness and co‐occurring substance misuse Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance… (2018) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs piperacetazine Mental state: specific ‐ clinically important change in negative symptoms · people with schizophrenia Chlorpromazine versus piperacetazine for schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs piperacetazine Economic costs · people with schizophrenia Chlorpromazine versus piperacetazine for schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Mirtazapine adjunct vs placebo adjunct Quality of life: clinically important change · schizophrenia Mirtazapine adjunct for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Mirtazapine adjunct vs placebo adjunct Service utilisation: number of days in hospital · schizophrenia Mirtazapine adjunct for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Activities of daily living · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Global state · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Social functioning · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Adverse effect · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Quality of life · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Employment status · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
Occupational therapy delivered by specialists vs delivery by non‐specialists Service use · adults with schizophrenia Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia (2018) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013) Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013) Adverse effects: weight gain · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001) Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + RISPERIDONE vs CLOZAPINE + SULPIRIDE (Kong 2001) Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) Adverse effects: weight gain · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013) Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ZIPRASIDONE vs CLOZAPINE + QUETIAPINE (Wen 2015) Adverse effects: weight gain · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ZIPRASIDONE vs CLOZAPINE + QUETIAPINE (Wen 2015) Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ZIPRASIDONE vs CLOZAPINE + QUETIAPINE (Wen 2015) Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013) Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CLOZAPINE + ARIPIPRAZOLE vs CLOZAPINE + HALOPERIDOL (Cipriani 2013) Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day) Adverse event: death · people with schizophrenia Chlorpromazine dose for people with schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Intensive Case Management vs non‐Intensive Case Management Global state: 1. Relapse ‐ by long term · people with severe mental illness Intensive case management for severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
Intensive Case Management vs non‐Intensive Case Management Mental state: not improved to an important extent ‐ by long term · people with severe mental illness Intensive case management for severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
Intensive Case Management vs standard care Global state: 1. Relapse ‐ by long term · people with severe mental illness Intensive case management for severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
Intensive Case Management vs standard care Mental state: not improved to an important extent ‐ by long term · people with severe mental illness Intensive case management for severe mental illness (2017) · Cochrane | no estimate extracted | NR | No studies |
Combinations of antipsychotic drugs vs single antipsychotic drugs Service utilisation: Change in hospital status ‐ not reported · schizophrenia or related disorders Antipsychotic combinations for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE Specific behaviours ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) (2017) · Cochrane | no estimate extracted | NR | No studies |